Skip to main navigation Skip to search Skip to main content

Mesoporous silica/organosilica nanoparticles for cancer immunotherapy

  • Shevanuja Theivendran
  • , Sergei Lazarev
  • , Chengzhong Yu*
  • *Corresponding author for this work
  • University of Queensland

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer is one of the fatal diseases in the history of humankind. In this regard, cancer immunotherapeutic strategies have revolutionized the traditional mode of cancer treatment. Silica based nano-platforms have been extensively applied in nanomedicine including cancer immunotherapy. Mesoporous silica nanoparticles (MSN) and mesoporous organosilica nanoparticles (MON) are attractive candidates due to the ease in controlling the structural parameters as needed for the targeted immunotherapeutic applications. Especially, the MON provide an additional advantage of controlling the composition and modulating the biological functions to actively synergize with other immunotherapeutic strategies. In this review, the applications of MSN, MON, and metal-doped MSN/MON in the field of cancer immunotherapy and tumor microenvironment regulation are comprehensively summarized by highlighting the structural and compositional attributes of the silica-based nanoplatforms.

Original languageEnglish
Article number20220086
JournalExploration
Volume3
Issue number3
DOIs
StatePublished - Jun 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cancer
  • immunotherapy
  • nanoparticles
  • organosilica
  • silica

Fingerprint

Dive into the research topics of 'Mesoporous silica/organosilica nanoparticles for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this